EUR 23.6
(1.72%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 4.22 Million EUR | -1220.82% |
2022 | -22.75 Million EUR | -273.89% |
2021 | 13.08 Million EUR | -78.74% |
2020 | 61.56 Million EUR | 1198.15% |
2019 | -5.6 Million EUR | -177.81% |
2018 | 7.2 Million EUR | 372.46% |
2017 | 1.52 Million EUR | -97.66% |
2016 | 65.21 Million EUR | 4.31% |
2015 | 62.51 Million EUR | 474.83% |
2014 | 10.87 Million EUR | 149.28% |
2013 | 4.36 Million EUR | 93.19% |
2012 | 2.25 Million EUR | -63.56% |
2011 | 6.19 Million EUR | -17.86% |
2010 | 7.54 Million EUR | 80.25% |
2009 | 4.18 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 8.41 Million EUR | 0.0% |
2023 FY | -300.6 Million EUR | -1220.82% |
2023 Q4 | 11.56 Million EUR | 0.0% |
2023 Q2 | 15.78 Million EUR | 0.0% |
2022 Q4 | 35.7 Million EUR | 0.0% |
2022 FY | -22.75 Million EUR | -273.89% |
2022 Q2 | 36.75 Million EUR | 0.0% |
2021 Q2 | 588.6 Thousand EUR | 0.0% |
2021 FY | 13.08 Million EUR | -78.74% |
2021 Q4 | 21.66 Million EUR | 0.0% |
2020 Q2 | 38.71 Million EUR | 0.0% |
2020 Q4 | 35.68 Million EUR | 0.0% |
2020 FY | 61.56 Million EUR | 1198.15% |
2019 Q2 | 18.17 Million EUR | 0.0% |
2019 FY | -5.6 Million EUR | -177.81% |
2019 Q4 | 1.74 Million EUR | 0.0% |
2018 Q4 | 6.18 Million EUR | 0.0% |
2018 FY | 7.2 Million EUR | 372.46% |
2018 Q2 | 1.02 Million EUR | 0.0% |
2017 Q2 | 9.69 Million EUR | 0.0% |
2017 FY | 1.52 Million EUR | -97.66% |
2017 Q4 | 8.17 Million EUR | 0.0% |
2016 Q4 | 51.64 Million EUR | 0.0% |
2016 FY | 65.21 Million EUR | 4.31% |
2016 Q2 | 13.56 Million EUR | 0.0% |
2015 Q4 | 67.72 Million EUR | 0.0% |
2015 Q2 | 5.2 Million EUR | 0.0% |
2015 FY | 62.51 Million EUR | 474.83% |
2014 FY | 10.87 Million EUR | 149.28% |
2014 Q2 | 2.72 Million EUR | 0.0% |
2014 Q4 | 8.14 Million EUR | 0.0% |
2013 FY | 4.36 Million EUR | 93.19% |
2013 Q4 | 2.09 Million EUR | 0.0% |
2013 Q2 | 2.26 Million EUR | 0.0% |
2012 Q4 | 2.51 Million EUR | 0.0% |
2012 Q2 | -1.57 Million EUR | -0.0% |
2012 Q1 | -1.57 Million EUR | 0.0% |
2012 FY | 2.25 Million EUR | -63.56% |
2012 Q3 | 2.51 Million EUR | 258.94% |
2011 FY | 6.19 Million EUR | -17.86% |
2010 FY | 7.54 Million EUR | 80.25% |
2009 FY | 4.18 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Apontis Pharma AG | 23.17 Million EUR | 81.78% |
Dermapharm Holding SE | 142.51 Million EUR | 97.038% |
Evotec SE | 222.55 Million EUR | 98.103% |
MERCK Kommanditgesellschaft auf Aktien | 8.82 Billion EUR | 99.952% |
PharmaSGP Holding SE | 50.72 Million EUR | 91.677% |
SynBiotic SE | 1.5 Million EUR | -180.239% |